Merrill Cuts OSI Pharmaceuticals to Neutral

Analyst Eric Ende says investors should show caution, despite positive trial results for lung-cancer drug Tarceva

Merrill Lynch downgraded OSI Pharmaceuticals (OSIP ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.